tDCS & the Peer-Reviewed Literature: What We Know Now
- jrotenberg3
- May 13
- 8 min read
Evidence Update
A condition-by-condition review of clinical trial evidence for transcranial direct current stimulation across eight neurological and developmental diagnoses
Joshua Rotenberg, MD | Pediatric Neurology & Sleep Medicine | Houston, TXSee the full tDCS Literature Library for PubMed collection links by topic.
What is tDCS? Transcranial direct current stimulation delivers a small, constant electrical current (typically 1–2 mA) between two scalp electrodes for 20–30 minutes. Anodal stimulation broadly increases cortical excitability; cathodal stimulation reduces it. The device is portable, generally well-tolerated, and inexpensive relative to pharmaceutical or surgical options. Over the past decade the published literature has expanded dramatically—below I summarize where things stand for the eight conditions I track in our NCBI literature library.
🧠
ADHD
ADHD has become one of the most studied indications for tDCS in pediatric neurology. The dominant protocol targets the dorsolateral prefrontal cortex (DLPFC)—the hub of executive function—with anodal stimulation over the left F3 position in the standard 10-20 EEG system.
A 2025 meta-analysis published in Activitas Nervosa Superior pooled seven randomized controlled trials (290 patients) and found that active tDCS significantly reduced both impulsivity (SMD = −0.60) and inattention (SMD = −1.00) compared with sham, without increasing adverse events. An independent 2025 systematic review of 11 controlled studies in adults (415 participants) published in Journal of Affective Disorders found domain-specific improvements in inattention and inhibitory control, though effect sizes were heterogeneous and the authors called for larger, better-standardized trials. An earlier landmark meta-analysis of 13 RCTs (2021) established that tDCS produced immediate improvements in overall symptom severity and inattention, with effects that persisted at follow-up—notable given that most neuromodulation effects in other conditions are transient.
Children and adolescents represent a growing subgroup. A 2025 meta-analysis focused exclusively on pediatric behavioral outcomes found favorable effect sizes on parent-rated symptoms immediately post-treatment. The most consistent protocol uses anodal left DLPFC stimulation, though right inferior frontal gyrus targeting has been explored for impulsivity with less consistent results.
PromisingMultiple RCTs
🎯
Ataxia
Cerebellar ataxias—whether hereditary spinocerebellar types, Friedreich's ataxia, or idiopathic degenerative forms—are notoriously difficult to treat pharmacologically. Cerebellar tDCS has emerged as one of the most scientifically coherent applications of the technology, given that the cerebellum is accessible to transcranial current and plays a central role in motor coordination and adaptation.
A Columbia/Johns Hopkins meta-analysis (Chen et al., Cerebellum, 2021) pooled five RCTs and found a 26% improvement in ataxia rating scores immediately post-treatment, with sustained effects through three months (28% improvement). Gait was the domain with the largest and most consistent benefit. A 2023 sham-controlled RCT in Movement Disorders demonstrated that anodal cerebellar tDCS significantly reduced both motor and cognitive symptoms in Friedreich's Ataxia specifically. A 2024 three-way crossover trial published in Cerebellum compared cerebellar tDCS, cerebellar transcranial alternating current stimulation (tACS), and sham in neurodegenerative ataxia using wearable gait sensors, finding both active modalities superior to sham.
The most common protocol uses 2 mA anodal stimulation over the cerebellum (posterior fossa, midline or slightly lateral) with a contralateral shoulder or buccinator cathode. Session blocks of 10–20 consecutive days appear more effective than single sessions. A combined cerebello-spinal approach (cerebellar anode + spinal cathode) is under active investigation in multicenter trials.
PromisingMultiple RCTs
🔗
Autism Spectrum Disorder (ASD)
Autism presents a compelling theoretical target for tDCS because the core social-communication deficits are linked to prefrontal and temporal-parietal dysregulation—circuits accessible to surface stimulation. A 2021 meta-analysis (García-González et al., European Neuropsychopharmacology) covering 16 studies found improvements in social, health, and behavioral problem domains on the Autism Treatment Evaluation Checklist, with anodal left DLPFC stimulation the most tested approach.
The most rigorous pediatric trial to date was a 2023 three-arm, double-blind RCT (Autism journal, Han et al.) involving 105 adolescents aged 14–21 with ASD. Participants receiving 10 days of prefrontal tDCS paired with cognitive remediation training showed significant improvements in overall social functioning and restricted/repetitive behaviors on the Social Responsiveness Scale-2 (effect size d = 0.61–0.88), while the sham group showed no significant change versus waitlist. A 2024 network meta-analysis of 14 non-invasive brain stimulation interventions for ASD (16 studies, N = 709) found that only anodal tDCS over left DLPFC with extracephalic cathode showed statistically significant improvement in autistic symptoms versus sham (SMD = −1.40).
High-definition tDCS (HD-tDCS), which focuses current more precisely than conventional pad electrodes, has also been piloted in ASD with sensory processing abnormalities, showing improvements in social awareness and autistic mannerisms in a 2025 RCT published in Scientific Reports.
PromisingRCTs available
⚡
Brain Injury & Disorders of Consciousness
Among the most emotionally charged applications of tDCS is its use in disorders of consciousness (DoC)—vegetative state and minimally conscious state (MCS)—where pharmacological options are limited and families are desperate for any viable intervention. The rationale is straightforward: DLPFC tDCS may activate frontoparietal networks that underlie conscious awareness and command-following.
Early open-label and small controlled studies showed signals of behavioral improvement on the Coma Recovery Scale-Revised (CRS-R), leading to cautious optimism. However, a 2022 individual patient data (IPD) meta-analysis published in Annals of Neurology pooled five recent RCTs and found no statistically significant group-level treatment effect, though subgroup analyses suggested patients in MCS (versus vegetative state) and those with traumatic rather than anoxic etiology may respond better. Methodological heterogeneity—particularly in stimulation parameters, session number, timing post-injury, and outcome measurement—remains the central challenge for interpreting the literature.
Current consensus supports tDCS over DLPFC as a low-risk, non-invasive option to consider, particularly in subacute traumatic MCS, while acknowledging that large, well-powered multicenter RCTs are needed before any firm clinical recommendations can be made. The safety profile is excellent.
Mixed ResultsEmerging
🦾
Cerebral Palsy
Cerebral palsy is the most common cause of pediatric motor disability, and the primary motor cortex (M1) is both the site of injury and the target of greatest interest for tDCS. The theoretical basis is well-established: in unilateral spastic CP, the contralesional hemisphere may be hyperexcitable and suppress the affected hemisphere via transcallosal inhibition. tDCS can reduce contralesional excitability (cathodal) while boosting the affected M1 (anodal), or both simultaneously with bilateral montages.
A landmark 2025 meta-analysis (Developmental Medicine & Child Neurology, Kim et al., Boston University) pooled studies through 2025 and found that anodal tDCS applied to M1 significantly improved motor function in children with CP, with effects amplified when paired with task-specific therapy. A separate 2025 systematic review and meta-analysis from Guangzhou Women and Children's Medical Center focused on mobility and balance, finding meaningful gains on the Gross Motor Function Measure (GMFM) and balance scales in children receiving combined tDCS and rehabilitation versus rehabilitation alone.
Electrode placement debates continue: bihemispheric protocols (anodal ipsilesional + cathodal contralesional) are increasingly favored over unilateral montages. Timing relative to therapy sessions also matters—most protocols now administer tDCS immediately before or during motor training to capitalize on primed neuroplasticity.
PromisingMultiple RCTs
🌤️
Depression
Depression is the indication with the largest and most mature tDCS literature. The canonical protocol uses anodal stimulation over the left DLPFC (F3) and cathodal over the right DLPFC (F4)—targeting the well-documented left hypoactivation/right hyperactivation pattern in major depressive disorder (MDD). This mirrors the rationale for left-sided repetitive TMS, which has FDA clearance for depression.
The most impactful recent development has been home-based tDCS. A 2024 randomized Phase 2 trial published in Nature Medicine (Woodham et al., UK/USA, N = 174) found that 10 weeks of self-administered tDCS with remote supervision produced significant mood improvement versus sham in moderate-to-severe MDD. Separately, a 2024 JAMA Psychiatry RCT by Borrione et al. confirmed home-use tDCS efficacy for acute depressive episodes. A comprehensive JAMA Network Open meta-analysis of 88 RCTs (5,522 participants), published in 2025, found tDCS associated with positive outcomes in MDD and in depression comorbid with psychiatric or medical conditions.
High-definition tDCS (HD-tDCS) targeted to the left DLPFC using MRI-guided individualized electrode placement showed statistically significant mood improvement over sham in a 2025 UCLA RCT (JAMA Network Open, Jog et al.), suggesting that spatial precision may enhance efficacy beyond conventional pad electrodes. The convergence of telehealth supervision models and consumer-grade tDCS hardware is positioning home-based depression treatment as a near-term clinical reality.
Strong Evidence88 RCTs analyzed
📖
Dyslexia
Developmental dyslexia involves disrupted phonological processing linked to atypical activation of the left temporoparietal cortex—the very region that tDCS can target with anodal stimulation to enhance cortical excitability. This makes dyslexia a theoretically well-grounded target for neurostimulation-assisted reading intervention.
A 2022 systematic review (Brain and Behavior, Salehinejad et al.) covering 35 studies across ADHD, ASD, and dyslexia found tDCS safe across 6,587 sessions in 745 children and adolescents, with no serious adverse events reported. For dyslexia specifically, left temporoparietal anodal stimulation was identified as the most consistent protocol for improving reading outcomes. A 2022 crossover RCT from Bambino Gesù Children's Hospital in Rome found that a short, intensive tDCS course significantly improved non-word reading speed immediately and at one-month follow-up compared with sham. A 2025 scoping review confirmed that tDCS—both alone and combined with phonological awareness training—produces meaningful gains in decoding speed, non-word reading accuracy, and text fluency in children with developmental dyslexia.
Combining tDCS with active reading or phonological training during stimulation (concurrent delivery) appears consistently superior to stimulation alone, supporting a model where tDCS amplifies learning-driven plasticity rather than substituting for it. This has practical implications: tDCS could be a scalable add-on to existing evidence-based reading curricula.
PromisingProtocol refinement ongoing
🫁
Long COVID (Post-Acute Sequelae of SARS-CoV-2)
Long COVID or PASC (Post-Acute Sequelae of SARS-CoV-2) is the newest indication in the tDCS literature and the one where evidence is most nascent but urgency is highest. Neuropsychiatric PASC—characterized by cognitive fog, fatigue, attention impairment, and mood symptoms—maps well onto prefrontal circuit dysfunction, making tDCS a logical candidate.
The field's most consequential data came from the NIH RECOVER-NEURO trial, a 5-arm, 22-site RCT conducted August 2023–June 2024 and published in JAMA in 2025. This trial randomized participants with cognitive long COVID to computerized cognitive training (BrainHQ), BrainHQ + tDCS, BrainHQ + cognitive-behavioral rehabilitation, an active comparator, or sham tDCS + BrainHQ. The tDCS + BrainHQ arm showed meaningful cognitive benefits, though the trial's design made isolating the tDCS contribution complex. A 2024 double-blind sham-controlled trial from the Czech Republic's National Institute of Mental Health (Klírová et al., Scientific Reports) tested 20 sessions of prefrontal tDCS in 33 patients with neuropsychiatric PASC featuring chronic fatigue. While both active and sham groups showed fatigue reduction, the intergroup difference did not reach significance—highlighting the challenge of high placebo response rates in this population and the need for larger samples.
A 2025 randomized controlled trial (Brain Stimulation) specifically targeting cognitive fatigue in long COVID found that repetitive anodal tDCS over the prefrontal cortex significantly reduced fatigue scores versus sham. The field is moving quickly: tDCS represents an accessible, home-deployable, low-risk option that could complement cognitive rehabilitation programs for the millions affected by this condition.
EmergingMixed Results
Evidence at a Glance
Condition | Evidence Level | Key Protocol Target | Notable Recent Trial |
ADHD | Promising | Left DLPFC (anodal) | Meta-analysis, 7 RCTs, 290 pts (2025) |
Ataxia | Promising | Cerebellum (anodal) | Friedreich's RCT, Mov Disord (2023) |
Autism (ASD) | Promising | Left DLPFC (anodal) | Triple-arm RCT, N=105 adolescents (2023) |
Brain Injury / DoC | Mixed | Left DLPFC (anodal) | IPD meta-analysis, 5 RCTs (2022) |
Cerebral Palsy | Promising | M1 ipsilesional (anodal) | Meta-analysis, DMCN (2025) |
Depression | Strong | Left DLPFC (anodal) | 88-RCT meta-analysis, JAMA (2025) |
Dyslexia | Promising | Left temporoparietal (anodal) | Scoping review, 2025; RCT 2022 |
Long COVID | Emerging | Prefrontal (anodal) | RECOVER-NEURO trial, JAMA (2025) |
The tDCS literature has matured considerably since the original version of this library was posted in 2019. Depression now has the strongest evidence base, with multiple large RCTs and home-delivery feasibility established. ADHD, ataxia, autism, cerebral palsy, and dyslexia all have promising signals from controlled trials, though sample sizes remain modest and protocol standardization is still evolving. Brain injury and long COVID are the most complex and heterogeneous groups, with high-quality trials underway. I will continue updating the PubMed literature collections as evidence accumulates.
— Dr. Josh RotenbergBoard-Certified Pediatric Neurologist | Epilepsy | Sleep MedicineNeurology & Sleep Specialists, PLLC · Houston, TX · myspecialist.clinic
Important Notice: This blog post is for educational and informational purposes only and does not constitute medical advice. The information provided here summarizes published peer-reviewed literature and should not be used as a substitute for professional medical evaluation, diagnosis, or treatment. There may be significant individual variation in response to tDCS. Consult a board-certified physician before considering any neuromodulation intervention. If you have a medical emergency, call 911.
Comments